Market Access Lessons For Cell And Gene Therapies In Germany

Companies Can Learn From Bluebird Bio’s Failed Zynteglo Pricing Deal

Lawyer and industry expert Alexander Natz sets out some important dos and don’ts for securing a successful launch of an advanced therapy in Germany.

German Flag
Zynteglo offers a cautionary tale for launching ATMPs in Germany • Source: Alamy

Unhappy with the price that was to be allowed in Germany for its gene therapy Zynteglo, bluebird bio withdrew the product from the market.

About The Author

Dr Alexander Natz is a lawyer and the founder of the Düsseldorf-based law firm Novacos Rechtsanwälte. Email: alexander.natz@novacos-law.com

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography